Harvard Bioscience Reports Strong Q2 Revenue Growth in 2026
Harvard Bioscience (HBIO) reported second-quarter revenue of $22.7 million for the period ending August 11, 2026, representing an 11% year-over-year increase driven by strong demand from CRO customers and robust sales in its Contract Manufacturing & Testing (CMT) portfolio. The company's adjusted gross margin was reported at 57%, slightly below expectations due to higher-than-anticipated lower-margin sales of CMT products and increased activity in China. Adjusted EBITDA for the quarter reached $1.7 million, up 11% year-over-year. The CEO highlighted strategic initiatives such as Project Viking—focused on footprint consolidation—and improvements in commercial alignment contributing to this performance. The company raised its full-year revenue outlook based on strong operational execution and growing adoption of its products by researchers seeking more predictive data for preclinical translational research.
Tickers: $HBIO
Topics: financial results Q2 earnings call